Browsing Tag
Insilico Medicine
4 posts
Insilico Medicine’s AI drug enters Phase III dosing. Can rentosertib clear the real test?
Insilico Medicine has dosed the first patient in its 320-patient Phase III GENESIS-IPF-3 study, moving rentosertib from an intriguing AI-drug discovery milestone into a year-long test of whether its earlier lung-function signal can survive pivotal clinical scrutiny.
Insilico Medicine just doubled down on CNS with Tenacia. Here’s why that matters now.
Insilico Medicine has expanded its Tenacia CNS partnership in a deal worth up to $94.75 million. Read what it signals for AI drug discovery now.
Can Insilico Medicine’s PandaClaw agentic AI platform accelerate pharma software licensing revenue growth in 2026?
Insilico Medicine launches PandaClaw, an agentic AI tool that lets biologists run autonomous multi-omics drug discovery analysis. Read what it means for pharma.
Insilico Medicine, Hygtia Therapeutics to advance AI-designed NLRP3 inhibitor for CNS diseases
Insilico and Hygtia partner to advance ISM8969, a brain-penetrant AI-designed NLRP3 inhibitor for CNS diseases. Find out what this means for the field.